Ignite Creation Date:
2024-05-05 @ 11:24 AM
Last Modification Date:
2024-10-26 @ 9:06 AM
Study NCT ID:
NCT00027066
Status:
COMPLETED
Last Update Posted:
2011-06-17
First Post:
2001-11-20
Brief Title:
Warfarin Versus Aspirin Recurrent Stroke Study
Sponsor:
Columbia University
Organization:
Columbia University
Study Overview
Official Title:
A Comparison of Warfarin and Aspirin for the Prevention of Recurrent Ischemic Stroke
Status:
COMPLETED
Status Verified Date:
2011-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this study is to compare aspirin to warfarin for the prevention of recurrent stroke
Detailed Description:
This study compared aspirin to warfarin to determine optimal therapy for the prevention of recurrent stroke Both drugs slow clotting of the blood Blood clots are involved in the final stages of the most common type of stroke due to blockage of the vessels that supply oxygen-rich blood to the brain Aspirin affects the blood platelets while warfarin inhibits circulating clotting proteins in the blood Numerous previous studies have proven that use of aspirin reduces recurrent stroke by about 25 percent Part of the controversy about aspirin versus warfarin for stroke prevention has been the thinking among clinicians that warfarin may be a better blood thinner than aspirin to prevent almost all forms of stroke but that it has greater side effects increased risk of hemorrhage and higher costs due to the need for blood tests to monitor the treatment effect for patients
To make the aspirin and warfarin arms of the study as unbiased as possible the investigators matched both groups of patients for primary stroke severity age gender education and raceethnicity The two groups were also matched for stroke risk factors including hypertension diabetes cardiac disease smoking alcohol consumption and physical activity The investigators used an aspirin dose of 325 mgday and a warfarin dose specifically tailored to each individual patient
This study found that aspirin works as well as warfarin in helping to prevent recurrent strokes in most patients
To make the aspirin and warfarin arms of the study as unbiased as possible the investigators matched both groups of patients for primary stroke severity age gender education and raceethnicity The two groups were also matched for stroke risk factors including hypertension diabetes cardiac disease smoking alcohol consumption and physical activity The investigators used an aspirin dose of 325 mgday and a warfarin dose specifically tailored to each individual patient
This study found that aspirin works as well as warfarin in helping to prevent recurrent strokes in most patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R01NS028371 | NIH | None | httpsreporternihgovquickSearchR01NS028371 |